Autopsy report · NCT06160609

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

“The study was terminated due to lack of efficacy.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 years 2 months after it had already started.
• Ran for about 3 years 3 months before it stopped.
• 9 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

Belantamab Mafodotin; GSK3174998

Participants

9

Sites

3

Countries

Australia, Canada, Sweden

Trials that died the same way

• Dasatinib in Polycythemia Vera
  “This study was terminated due to lack of efficacy.” (99% match in meaning)
• A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
  “This study was terminated due to a lack of efficacy.” (98% match in meaning)
• A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  “The study was early terminated due to lack of efficacy.” (98% match in meaning)
• A Study of LY3405105 in Participants With Advanced Cancer
  “The study was terminated for lack of sufficient efficacy.” (97% match in meaning)
• Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer
  “Study was terminated early due to a lack of improved efficacy.” (94% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.